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The ability to reprogram somatic cells to induced pluripotent stem cells (iPSCs) has revolutionized the field of
regenerativemedicine. However, recent studies on the genetic and epigenetic variations in iPSCs have raised
concerns that these variationsmay compromise the utility of iPSCs. In this Perspective, we review the current
understanding of genetic and epigenetic variations in iPSCs, trace their causes, discuss the implications of
these variations for iPSC applications, and propose approaches to cope with these variations.Introduction
iPSCs, derived from transcription-factor-mediated reprogram-
ming, are pluripotent stem cells (PSCs) with molecular and
functional properties similar to embryonic stem cells (ESCs)
(Stadtfeld and Hochedlinger, 2010). The iPSC technology holds
tremendous promise for regenerative medicine. iPSCs offer
autologous cell sources for replacement therapy, and patient-
specific iPSCs can serve as in vitro models for disease mecha-
nism studies and drug screening (Robinton and Daley, 2012).
Yet, this promise is obscured by recent findings of genetic and
epigenetic variations in iPSCs. These variations exist between
iPSC lines, between iPSC and ESC lines, between different
passages of the same iPSC line, and even between different
populations at a specific passage of the same iPSC line. Such
variations potentially affect the properties of iPSCs and under-
mine their accountability in downstream applications. In this
Perspective, we discuss the genetic and epigenetic variations
in iPSCs and their causes, the implications of these variations
in iPSC applications, and potential approaches to cope with
these variations.
Genetic Variations in iPSCs
An iPSC genome may harbor a wide range of variations,
including aneuploidy, subchromosomal copy number variation
(CNV), and single nucleotide variations (SNVs). These variations
can be introduced into the iPSCs from different sources during
iPSC generation and maintenance (Figure 1). First, genetic vari-
ations in iPSCs may originate from the heterogeneous genetic
makeup of source cell population. Due to the low efficiency
and clonal nature of iPSC derivation, individual iPSC lines are
capable of capturing genetic variations from individual starting
cells, even if the variations only occur at low frequencies among
the source cells (Figure 1AI). Moreover, if certain genetic varia-
tions in source cells facilitate the derivation of iPSCs, those var-
iations will be preferentially propagated in the derived iPSC
lines (Figure 1AII). Second, the reprogramming process may be
mutagenic, which potentially introduces de novo variations
(Figure 1B). Third, like ESCs, prolonged culturing of iPSCs mayintroduce or select for genetic alterations that facilitate cell prop-
agation (Figure 1C). In addition to these causes, certain varia-
tions may arise from innate genetic instability of the in vitro
pluripotent state. In the following sections, we will discuss
each type of genetic variation and look into its potential causes.
Aneuploidy
Recurrent aneuploidy. Aneuploidy, an abnormality in chromo-
some number, is frequently reported in in vitro cultured PSCs,
including iPSCs and ESCs. One comprehensive study by the
International Stem Cell Initiative revealed that approximately
one in three analyzed human ESC (hESC) or iPSC (hiPSC) lines
have karyotype abnormalities in at least one passage (Amps
et al., 2011), while a second study estimated that 13% of
hESC and hiPSC cultures bear aberrant karyotypes (Taapken
et al., 2011). Recurrent gains of specific chromosomes account
for more than half of the total karyotype abnormalities, with tri-
somy 12 being the most common in both hESCs and hiPSCs.
Other less frequent whole-chromosome gains include trisomy
of chromosome 8 and chromosome X (Amps et al., 2011; May-
shar et al., 2010; Taapken et al., 2011). For unknown reasons,
trisomy 17, which occurs frequently in hESCs, is rarely detected
in hiPSCs (Mayshar et al., 2010; Taapken et al., 2011). In mouse
ESC (mESC) and iPSC (miPSC) lines, whole-chromosome gain
occurs frequently for chromosomes 8 and 11, and the latter
shares significant syntenic regions with human chromosome
17 (Ben-David and Benvenisty, 2012).
The recurrent aneuploidy patterns in PSCs have long been
thought to reflect the adaptation of these cells to their in vitro cul-
ture conditions (Baker et al., 2007). The occurrence frequency
generally increases through continuous passaging, although
the abnormalities can be detected at early passages, and normal
karyotypes can be found at late passages (Amps et al., 2011;
Taapken et al., 2011). In addition, recurrent aneuploidy can be
detected in a particular subpopulation of hESC or hiPSC culture.
The fact that these subpopulations expand along passaging
suggests that the abnormalities are positively selected during
culturing (Amps et al., 2011; Mayshar et al., 2010; Taapken






















Figure 1. Sources of Genetic Variations in iPSC Lines
Genetic variations of iPSC lines may have different sources.
(A) Individual starting somatic cells (diamond) within a culture (rounded rectangle) bear subtle genetic variations (colored crosses), which can be captured and
manifested in the iPSC (circle) lines for the clonal nature of the transcription factor (TF)-mediated iPSC derivation process. (AI) Given that reprogramming occurs
stochastically among the starting cell population, the genetic variations captured in iPSC lines may have random patterns. (AII) If reprogramming preferentially
takes place in cells bearing genetic variations conferring selective advantage (green crosses), the iPSC-manifested variations may show functional enrichment.
(B) The reprogramming process per se may introduce variations. The cells that undergo reprogramming may have enhanced genomic instability (striped circles),
resulting in de novo mutations in iPSCs. Early-passage iPSCs may display mosaicism of de novo mutations, which are subjected to selection along passaging.
Mutations conferring advantage in self-renewal or proliferation (green crosses) eventually prevail the culture; those deleterious for cell survival (red crosses) are
selected against in culture; while other neutral mutations (crosses with other colors) undergo genetic drift.
(C) Mutations that arise during prolonged culturing are subjected to similar selection patterns described in (B).
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beneficial for self-renewal or proliferation. For example, human
chromosome 12 harbors pluripotency genes NANOG and
GDF3, which may explain the frequent trisomy of this chromo-
some in cultured hESC and hiPSC lines (Draper et al., 2004;
Mayshar et al., 2010). Despite a general correlation between
recurrent aneuploidy and prolonged culturing, it is not clear
whether whole-chromosome stability is generally compromised
in PSCs.
Aneuploidy from the source cells in iPSC generation. While
both ESCs and iPSCs are subject to the risk of acquiring aneu-
ploidy due to long-term culturing and/or their innate properties,
the chromosomal states of iPSCs can also be influenced by
source cells and the reprogramming process. In fact, transcrip-
tion-factor-mediated reprogramming has been shown to be
compatible with aneuploid starting cells. Fibroblasts with trisomy
21 from Down syndrome patients can be successfully reprog-
rammed into iPSCs (Park et al., 2008). One study on trisomy
21 iPSCs containing a selectable transgene on one copy of chro-
mosome 21 showed that the rate of spontaneous loss of this150 Cell Stem Cell 13, August 1, 2013 ª2013 Elsevier Inc.chromosome is approximately 104 (Li et al., 2012a); however,
it is unknown whether euploid or other aneuploid iPSCs bear
a similar rate of chromosome loss. Furthermore, iPSCs can
also be derived from mouse embryonic fibroblasts (MEFs) in
aneuploid-susceptible genetic backgrounds with efficiency
comparable to that of normal MEFs (Hamada et al., 2012). Inter-
estingly, high rates of aneuploidy in source cells do not always
translate into similarly high rates in the derived iPSC lines. Defi-
ciency in either BubR1, a core component of spindle assembly
complex, or RanBP2, a regulator of chromosome decatenation,
results in similarly high rates of aneuploidy in MEFs. However,
the aneuploidy rate is substantially different between the iPSC
lines from these two genetic backgrounds. While nearly all
iPSC lines with BubR1 deficiency show higher rates of aneu-
ploidy relative to the starting MEFs, iPSCs derived from
RanBP2-deficient background are largely devoid of aneuploidy
and even have a lower aneuploidy rate compared to wild-type
iPSCs (Hamada et al., 2012). It seems likely that aneuploidy
stemming from different causes may be subjected to different
selective pressures during reprogramming, resulting in different
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ploidy in iPSC lines can be inherited from source cells, but
whether reprogramming selects for or against aneuploidy
depends on how aneuploidy is generated.
Subchromosomal Variations
CNV. Similar to recurrent aneuploidy, hiPSCs and hESCs may
share Mb-scale CNVs, which can be detected by karyotyping
and gene expression meta-analysis. Some of these CNVs occur
at specific chromosomal locations, for example, around pluripo-
tency gene NANOG on human chromosome 12 and DNMT3B
on human chromosome 20 (Laurent et al., 2011; Martins-
Taylor et al., 2011; Mayshar et al., 2010). Such location prefer-
ences indicate that these CNVs may be selected during in vitro
propagation.
In addition, CNVs can be introduced into iPSCs from source
cells and/or during the reprogramming process. Comparative
genomic analyses based on single nucleotide polymorphism
(SNP) array detected high CNV frequency in hiPSCs when
compared to hESCs, source cells, or human non-PSCs (Hussein
et al., 2011; Laurent et al., 2011). The CNVs specifically detected
in iPSCs have been suspected to be generated from the reprog-
ramming process. One study showed that the iPSC-specific
CNVs constitute genetic mosaicism in iPSC lines at early pas-
sages. The mosaicism is gradually lost through passaging,
consistent with the finding that most of these CNVs are dele-
tions, which is likely disadvantageous to cell survival (Hussein
et al., 2011). Further investigation of the iPSC-specific CNVs
indicates they are enriched in common fragile sites where the
replication fork is inclined to stall and collapse (Hussein et al.,
2011). This leads to the hypothesis that the reprogramming pro-
cess de novo generates CNVs for the elevated replication stress
encountered by the reprogramming cells (Hussein et al., 2011,
2013). A second study reported the detection of high-frequency
deletions in early-passage iPSCs. Interestingly, many of the de-
letions occur near tumor suppressor genes, indicating potential
roles of these CNVs in reprogramming (Laurent et al., 2011).
However, neither the findings of early-passage mosaicism nor
CNV enrichment around tumor suppressor genes in iPSCs could
be confirmed in a later study (Abyzov et al., 2012). One caveat for
the array-based studies is that low-frequency variations in
source cells might be beyond the detection limit of this
approach. This limitation might explain the discrepancy between
results from the array-based studies (Hussein et al., 2011; Lau-
rent et al., 2011) and those from studies using next generation
sequencing, which is generally a more sensitive method (Abyzov
et al., 2012; Cheng et al., 2012; Gore et al., 2011; Quinlan et al.,
2011; Young et al., 2012).
Overall, sequencing-based studies have revealed much fewer
or no detectable de novo CNVs in iPSCs (Abyzov et al., 2012;
Cheng et al., 2012; Gore et al., 2011; Quinlan et al., 2011; Young
et al., 2012), arguing against the notion that the reprogramming
process is susceptible to de novo CNVs. In particular, one study,
which represents perhaps the most comprehensive study so far
of CNVs using a deep sequencing approach, showed that on
average each hiPSC line manifests only two CNVs that are unde-
tectable in the bulk population of starting fibroblasts (Abyzov
et al., 2012). However, at least half of the hiPSC-manifested
CNVs are present in rare populations (estimated to be <15%)
of parental fibroblasts when more sensitive PCR-based detec-tion is applied (Abyzov et al., 2012). This finding suggests that
iPSC generation does not necessarily lead to de novo generation
of CNVs. Instead, the low-grade genetic mosaicism of CNVs in
source cells is clonally captured by the iPSC derivation process.
Although it is possible that some of the CNVs might arise during
the reprogramming process, low-grade genetic mosaicism
of the somatic cells appears to be the major source of CNVs
in iPSCs.
SNV. SNVs have been studied in both hiPSC and miPSC lines
by high-throughput sequencing of whole genome or exome
(protein-coding regions). Genome-wide sequencing has re-
vealed more than a thousand SNVs for each examined hiPSC
line and hundreds of SNVs in the mouse counterpart (Cheng
et al., 2012; Young et al., 2012). The average numbers of SNVs
in protein-coding genes are estimated to be no more than a
dozen in an individual hiPSC or miPSC line (Cheng et al., 2012;
Gore et al., 2011; Ji et al., 2012; Ruiz et al., 2013; Young et al.,
2012). The number of SNVs in each iPSC line appears to be inde-
pendent of the delivery methods of reprogramming factors (viral
vector, episomal vector, or mRNA transduction) or source cell
types (Gore et al., 2011; Ruiz et al., 2013). Half or more than
half of the exome SNVs in iPSCs can be traced back to the
source cells (Gore et al., 2011; Young et al., 2012). It is therefore
important to note that to date only a single study has argued that
the majority of SNVs come from the reprogramming process
(Ji et al., 2012). However, the limited sequencing depth of this
studymay not have been able to uncover rare SNVs in the source
cells, leading to an overestimation of the SNVs generated during
reprogramming. In addition, mutation rate in the source cells
was not experimentally assessed in this study, which may also
contribute to the discrepancy. Therefore, although reprogram-
ming-induced point mutations cannot be excluded, source cell
contribution appears to be the major source of SNVs manifested
in iPSCs.
Several studies have also probed into the potential relation-
ship between SNVs and iPSC generation. Most studies revealed
no shared SNV between any of the iPSC lines examined (Cheng
et al., 2012; Gore et al., 2011; Ji et al., 2012; Ruiz et al., 2013),
suggesting the stochastic nature of iPSC generation and/or re-
programming-related mutagensis. However, one study showed
that, in one of the reprogramming experiments, all selected
iPSC clones shared a set of variations from somatic cells (Young
et al., 2012). This result raises the possibility that certain genetic
compositions of the source cells may favor reprogramming and
therefore be preferentially selected for during iPSC generation
(Figure 1AII). Nonetheless, it is currently unknown how this set
of variation confers a reprogramming advantage. While most of
the studies indicate no specific functional enrichment among
the genes displaying SNVs in iPSCs (Cheng et al., 2012; Ji
et al., 2012; Ruiz et al., 2013; Young et al., 2012), one report
claims that exome SNVs in hiPSCs are enriched in genes
mutated in certain cancers (Gore et al., 2011). However, these
SNVs are not detected at the mutated spots found in cancers,
nor are they shared by multiple iPSC lines, which would argue
against the idea that they are selected for their oncogenic poten-
tial. Moreover, a follow-up study examining the functionality of
iPSC-manifested SNVs indicates that, in general, genes with
these SNVs do not facilitate iPSC generation (Ruiz et al., 2013).
Thus, it seems that most iPSC-manifested SNVs are randomlyCell Stem Cell 13, August 1, 2013 ª2013 Elsevier Inc. 151
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generation.
p53 and DNA damage response in reprogramming and iPSC
genome integrity. Subchromosomal genome alteration, which
may contribute to CNVs or SNVs in iPSCs, mainly results from
DNA damage and unsuccessful damage repair. The tumor sup-
pressor p53 is a key protein that mediates the DNA damage
response (DDR) and guards genomic integrity. Recent studies
have demonstrated a role for p53 and DDR in iPSC generation.
It has been shown that gH2AX, a marker for DNA double-strand
breaks (DSBs), is elevated in at least a portion of reprogramming
cells, indicating that DSBs are triggered when reprogramming
is initiated (Gonzalez et al., 2013; Kawamura et al., 2009). This
might be due to the oncogenic properties of the reprogramming
factors as well as the genome editing activities of viral transduc-
tion used in reprogramming. It is believed that the highly prolifer-
ative program initiated by the reprogramming factors may cause
replication stress, which leads to genotoxicity and DDR (Hussein
et al., 2013). However, cells with gH2AX foci only account for a
minor population (1%–5%) of the cells undergoing reprogram-
ming (Gonzalez et al., 2013; Mario´n et al., 2009). Due to the
presence of p53, the cells with significant genomic lesions are
unlikely to proceed to the full iPSC state. Consistently, somatic
cells that are vulnerable to DNA damage, including those with
a deficiency in Atm (Kinoshita et al., 2011; Mario´n et al., 2009)
or Brca1/Brca2 (Gonzalez et al., 2013), display reduced reprog-
ramming capacity.
Concurrent with the DDR response, the p53 pathway is acti-
vated upon the induction of reprogramming factors (Banito
et al., 2009; Kawamura et al., 2009). As a result, most of the re-
programming cells undergo cell cycle arrest or apoptosis (Smith
et al., 2010). Given that p53 senses and integrates diverse stress
signals, activation of p53-related pathways can be due to DDR
and/or other stresses initiated by the reprogramming factors.
For example, oxidative stress is associated with an increase in
p53 levels in reprogramming cells (Utikal et al., 2009; Yoshida
et al., 2009). In contrast, ascorbate (or vitamin C), a scavenging
agent for reactive oxidative species, is capable of lowering p53
levels and enhancing reprogramming efficiency (Esteban et al.,
2010). Therefore, p53 presumably prevents stressed cells from
proceeding to pluripotency. Consistent with this notion, when
p53-deficient cells are subjected to reprogramming, cell prolifer-
ation is not checked under reprogramming-induced stresses,
leading to widespreadDNA lesions (Mario´n et al., 2009). Interest-
ingly, despite these lesions, reprogramming is able to proceed
due to the unchecked cell cycle in the p53-deficient cells, sug-
gesting that for the establishment of pluripotency, compromised
genome integrity may be tolerated to a certain extent. Conse-
quently, increased reprogramming efficiency is observed when
p53-deficient MEFs are used (Banito et al., 2009; Hanna et al.,
2009; Kawamura et al., 2009; Mario´n et al., 2009; Utikal et al.,
2009). Of note, although p53 deficiency appears to enhance
reprogramming efficiency, so far, to our knowledge, there is no
report for de novo p53 mutation found in iPSC lines, nor do
p53-deficient iPSCs bear increased mutation loads (Gore et al.,
2011). Thus, currently there is no definitive evidence for the
contribution of p53 to the genetic variations detected in iPSCs.
The DNA damage signaling and repair pathways utilized in
iPSCs are similar to those of ESCs, which are thought to have152 Cell Stem Cell 13, August 1, 2013 ª2013 Elsevier Inc.high efficiency and fidelity (Momcilovic et al., 2011). In ESCs,
the mutation rate is low, presumably because genes involved
in damage signaling and repair are expressed at high levels
compared to differentiated cells (Maynard et al., 2008;
Momcilovic et al., 2011). Furthermore, homologous recombina-
tion, a repair pathway more precise than nonhomologous end
joining, is preferred for damage repair in ESCs (Serrano et al.,
2011; Tichy et al., 2010). It has also been shown that, in ESCs
and iPSCs, cells with DNA damage can be effectively excluded
from the self-renewing pools by the induction of differentiation
(Li et al., 2012b; Lin et al., 2005) or apoptosis (Aladjem et al.,
1998). Therefore, it seems that after pluripotency is established,
genomic integrity is effectively safeguarded in the iPSC lines.
In summary, subchromosomal variations present in iPSCs are
mainly derived from source cells. These somatic genetic varia-
tions, even in low abundance, can be captured in the iPSC
generation process and can be amplified in the established
iPSC lines. The possible contribution of the iPSC generation pro-
cess to the variations remains to be shown. Isolating iPSC-
destined cells and monitoring their genomic integrity throughout
the reprogramming process should shed light on whether the
reprogramming process is mutagenic. Although DDR and the
p53 pathway are activated by the reprogramming factors, their
relevancy to the genetic variations of iPSCs remains to be
shown.
Epigenetic Variations in iPSCs
The generation of iPSCs involves resetting epigenetic land-
scapes (Liang and Zhang, 2013). However, due to incomplete
reprogramming, epigenetic variations may exist between ESCs
and iPSCs and between different iPSC lines. In addition, the
epigenetic status of the cells may change during prolonged
culturing, which can also contribute to epigenetic variations
observed in iPSCs. In this section, we will discuss these
epigenetic variations.
Variations in X Chromosome Inactivation
In mice and humans, female somatic cells achieve dosage
compensation through X chromosome inactivation (XCI), in
which one of the two X chromosomes is inactivated. During
reprogramming of mouse female somatic cells, the inactive X
chromosome (Xi) is reactivated, resulting in two active X chromo-
somes (XaXa) in miPSCs. The reactivated X chromosome is
capable of undergoing XCI, when miPSCs are induced to differ-
entiate (Maherali et al., 2007). These observations in miPSCs are
consistent with the epigenetic state of the X chromosomes in
mESCs. Unlike miPSCs/mESCs, hiPSCs/hESCs are highly vari-
able in terms of the epigenetic state of the X chromosomes
(Wutz, 2012). Under conventional derivation and culturing condi-
tions, the XaXi state from somatic cells is largely retained during
the reprogramming process (Anguera et al., 2012; Cheung et al.,
2011; Mekhoubad et al., 2012; Pomp et al., 2011; Tchieu et al.,
2010), although XaXa have been reported in some hiPSC lines
(Marchetto et al., 2010) or subpopulations of other lines (Anguera
et al., 2012). Upon differentiation, XaXa hiPSCs undergo XCI,
while XaXi cells keep their X chromosome status in differentiated
cells. Similar to hiPSCs, the XaXi status is also predominantly
detected in hESCs (Silva et al., 2008), suggesting that the XCI
status may reflect the innate properties of these human PSCs
or the culturing conditions that are commonly applied to them.
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shown by the tendency for cells to lose the inactive status of Xi
during prolonged culturing. The transcriptional repression of Xi
in XaXi hiPSCs is prone to defect in late passages, as shown
by loss of Xist expression and repressive chromatin modifica-
tions such as H3K27 methylation and DNAmethylation (Anguera
et al., 2012; Mekhoubad et al., 2012; Nazor et al., 2012; Silva
et al., 2008; Tchieu et al., 2010). This results in hiPSCs with
one Xa and one X chromosome with ‘‘eroded’’ inactivation
(Xe). While some reports suggest that Xe is still transcriptionally
inactive at certain examined loci (Anguera et al., 2012; Tchieu
et al., 2010), others show that erosion of XCI is associated with
increased gene expression (Mekhoubad et al., 2012; Nazor
et al., 2012). Importantly, XaXe cells appear to have a growth
advantage and gradually take over the hiPSC population. This
advantage is likely due to the enhanced expression of onco-
genes in XaXe hiPSC lines (Anguera et al., 2012; Mekhoubad
et al., 2012; Tchieu et al., 2010). Consistent with the potential
cancer-like properties, XaXe hiPSCs show inefficient differentia-
tion when subjected to differentiation cues. In addition, the
eroded state of Xe is also passed onto differentiated cells and
Xe never undergoes XCI, indicating different properties between
Xe and Xa (Anguera et al., 2012; Mekhoubad et al., 2012). Finally,
the erosion of Xi is also observed in hESC cultures (Silva et al.,
2008), again suggesting that the intrinsic properties of human
PSCs and/or their shared culturing conditions might be the
cause of the epigenetic variability on X chromosomes.
Variations in Local Epigenetic Status
Apart from the whole-chromosome epigenetic variability on the
X chromosome, iPSCs also bear local epigenetic variations in
other parts of the genome. Several studies have identified differ-
ences in epigenetic profiles between iPSC and ESC lines and
between iPSC lines. While histone modifications generally
show little difference (Chin et al., 2010; Guenther et al., 2010),
variations in DNA methylation have been reported in multiple
comparative studies (Bock et al., 2011; Lister et al., 2011;
Nishino et al., 2011; Ruiz et al., 2012). The variations in DNA
methylation in iPSCs can be attributed to either source cell
memory or aberrant methylation generated during reprogram-
ming. Continued passaging generally reduces the variations of
DNA methylation in iPSCs, although they may persist or, in
some cases, even increase with passaging (Nazor et al., 2012;
Nishino et al., 2011).
Source cell memory. Due to incomplete reprogramming,
hiPSC or miPSC lines may retain some of the epigenetic signa-
ture from source cells. One type of source cell memory is insuf-
ficient silencing of lineage-specific genes from the source cells.
At these loci, DNA hypomethylation and/or transcription-permis-
sive histone modifications are maintained in iPSCs similar to the
source cells (Bar-Nur et al., 2011; Kim et al., 2010, 2011; Lister
et al., 2011; Ohi et al., 2011; Polo et al., 2010; Ruiz et al.,
2012). Genome-wide DNA methylation analyses showed that
insufficient DNA methylation accounts for most memory-related
differentially methylated regions (DMRs) between hiPSCs and
hESCs (Lister et al., 2011; Ohi et al., 2011; Ruiz et al., 2012). In
addition, source cell memory also includes chromatin constraint
at gene loci that specify lineages other than source cells. These
loci are hypermethylated in iPSCs compared to ESCs, rendering
them incapable of being activated upon differentiation (Kim et al.,2010, 2011). Consequently, iPSCs with source cell memory
have skewed differentiation potentials in favor of the source
cell lineage (Bar-Nur et al., 2011; Kim et al., 2010, 2011; Polo
et al., 2010).
These remnant somatic epigenetic modifications can be
erased by continued passaging, cross-lineage differentiation fol-
lowed by serial reprogramming, or chemical inhibition of DNA
methylation and histone deacetylation (Kim et al., 2010; Polo
et al., 2010). The observation that iPSCs, at least in early pas-
sages, retain portions of the source cell DNAmethylation pattern
is consistentwith the finding that the resettingofDNAmethylation
patterns takes place late during the reprogramming process
and may remain incomplete after the establishment of iPSC
lines (Polo et al., 2012). Thus, incomplete reprogramming of
epigenetic profiles contributes to the differences between iPSCs
andESCsandbetween iPSCsderived fromdifferent source cells.
Aberrant DNA methylation. During reprogramming, DNA
methylation status may be erroneously altered, leading to
iPSC-specific DNA methylation patterns distinct from those in
source cells and ESCs. Depending on the loci, aberrant methyl-
ation can be specific for individual iPSC lines, or it can be
common to multiple iPSC lines. The iPSC-specific differentially
methylated loci include certain imprinted loci as well as other
genomic regions.
Genomic imprinted loci are expressed in an allele-specific
manner and are subject to regulation by allele-specific DNA
methylation. The radical change in the epigenetic landscape dur-
ing reprogramming raises concerns that such changes may
potentially interfere with the DNAmethylation status of imprinted
loci. Multiple studies in hiPSCs indicate that some imprinted loci
are vulnerable to epigenetic alteration during reprogramming or
prolonged culturing (Chamberlain et al., 2010; Nazor et al., 2012;
Nishino et al., 2011; Pick et al., 2009). Depending on specific loci,
reprogramming can induce either hypermethylation or hypome-
thylation. Extensive passaging of hiPSCs/hESCs is also associ-
ated with aberrant methylation status at some imprinted loci,
including H19 (Nazor et al., 2012; Nishino et al., 2011). The
DNA methylation changes, at least for some imprinted loci,
have been correlated with loss of allele-specific expression,
implicating a potential functional effect for these changes (Nazor
et al., 2012; Pick et al., 2009). In addition, studies in miPSCs
show that the imprinted locus Dlk1-Dio3 frequently undergoes
aberrant repression during the reprogramming process (Liu
et al., 2010; Stadtfeld et al., 2010). Decreased expression at
this locus has been shown to be the sole detectable difference
in gene expression between miPSCs and mESCs when effects
of genetic background are removed (Stadtfeld et al., 2010).
Aberrant silencing of this locus in iPSCs has been functionally
associated with failure to generate all-iPSC mice through tetra-
ploid complementation (Liu et al., 2010; Stadtfeld et al., 2010).
Interestingly, altering the stoichiometry of reprogramming fac-
tors (Carey et al., 2011) or including ascorbate in the reprogram-
ming cocktail (Stadtfeld et al., 2012) can avoid aberrant silencing
of the Dlk1-Dio3 locus, suggesting that optimization of the re-
programming protocol and/or culturing conditions can prevent
aberrant DNA methylation.
In addition to imprinted loci, reprogramming-induced aberra-
tions in DNA methylation have been found in other genomic
regions. Methylome profiling with whole-genome bisulphiteCell Stem Cell 13, August 1, 2013 ª2013 Elsevier Inc. 153
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be detected in both CG dinucleotides and non-CG sites. For CG
DMRs, hypomethylation in hiPSCs are prevalent for both mem-
ory-related and reprogramming-induced DMRs; however, all
hypermethylated CG DMRs in hiPSCs are recognized as re-
programming-induced aberrancies (Lister et al., 2011). Interest-
ingly, in another study using reduced representative bisulphite
sequencing (RRBS), hypermethylation was reported as the
predominant form of reprogramming-induced methylation
abnormality (Ruiz et al., 2012). The discrepancy between the
two studies may be from the selection of genomic regions in
the latter studies and/or line-specific differences of iPSCs.
With regard to non-CG DMRs, they are mainly found in Mb scale
at the regions proximal to centromeres and telomeres. Methyl-
ation at these regions appears to be depleted during reprogram-
ming because the regions are partially methylated in somatic
cells and highly methylated in ESCs, but hypomenthylated in
iPSCs (Lister et al., 2011). Interestingly, genomic sites enriched
for H3K9me3 has been found in these large iPSC-specific hypo-
methylated regions, indicating that the heterochromatic state
may interfere with the reprogramming events taking place in
these regions (Lister et al., 2011). A recent study suggests that
large-scale regional enrichment of H3K9me3 might be caused
by in vitro culturing (Zhu et al., 2013). Hence, culturing stress
might be partly responsible for the non-CG DNA methylation
aberrancy in iPSCs. Of note, reprogramming-induced epigenetic
abnormalities and their potential effect on transcription can be
transmitted through differentiation and can potentially alter
the properties of differentiated cells (Lister et al., 2011; Ruiz
et al., 2012).
To date, it remains controversial whether iPSCs can be distin-
guished from ESCs in terms of their epigenetic and/or tran-
scriptional profiles. In particular, some studies have identified
hotspots or sets of genes in hiPSCs whose DNA methylation
and transcription statuses are clearly different from that of
hESCs. The expression statuses of these ‘‘signature’’ genes,
including FAM19A5, FZD10, TCERG1L, and TEME132D, have
been reported by several groups to be different in hiPSCs and
hESCs (Lister et al., 2011; Nishino et al., 2011; Ruiz et al.,
2012). However, another comprehensive study concluded that
the variations of DNA methylation between hESCs and hiPSC
lines are not greater than those between different hESC lines
(Bock et al., 2011). The discrepancy between these studies is
probably due to the differences in sample size, iPSC derivation
methods, and methods of DNA methylation analysis. Neverthe-
less, for each iPSC line, cell-line-specific DNA methylation pat-
terns have been widely reported and have to be characterized
and considered when iPSCs are used for downstream functional
studies and therapeutic applications.
Application Concerns
The development of the iPSC technology has made the genera-
tion of patient-specific PSCs feasible and readily accessible
(Robinton and Daley, 2012). Patient-specific iPSCs can be
used not only for disease modeling but also for drug screening.
To realize the potential of the iPSC technology, concerns about
the genetic and epigenetic variations of iPSCs have to be
addressed.
One of the major concerns is whether the genetic and epige-
netic variations in iPSCs change their differentiation potential.154 Cell Stem Cell 13, August 1, 2013 ª2013 Elsevier Inc.Indeed, different lines of iPSCs have been shown to have varied
differentiation efficiency and developmental capacity (Feng
et al., 2010; Hu et al., 2010; Kim et al., 2010; Miura et al., 2009;
Polo et al., 2010; Stadtfeld et al., 2010). One of the causes for
the varied differentiation capacity is source cell memory, which
biases iPSC differentiation into the source cell lineage (Kim
et al., 2010, 2011; Polo et al., 2010). Aberrant epigenetic statuses
on certain loci (for example, the imprinted Dlk1-Dio3 locus) can
also contribute to differential developmental potentials (Liu
et al., 2010; Stadtfeld et al., 2010). Furthermore, culture-adapted
hiPSCs, often harboring recurrent aneuploidy, recurrent CNVs,
or eroded XCI, often differentiate poorly when subjected to
differentiation conditions (Ben-David and Benvenisty, 2011). In
addition, genetic variations inherited from source cells or
introduced during reprogramming might also affect iPSC dif-
ferentiation capacity, particularly when the variations occur at
developmentally important loci.
A second concern for disease modeling and cell replacement
therapy is that the genetic and epigenetic variations detected in
iPSCs may potentially cause unexpected phenotypic changes
after differentiation of iPSCs into target cells. For disease
modeling, this may lead to acquisition of disease-unrelated phe-
notypes or disappearance of disease-related phenotypes. A
recent study utilizing female hiPSCs to model the X-linked
Lesch-Nyhan syndrome (LNS) showed that, when extensively
passaged patient-specific hiPSCs are used for neural differenti-
ation, the neural disease phenotype caused by a mutated HPRT
gene on the active X chromosome can be rescued by expression
of the wild-type gene on the eroded inactive X chromosome
(Mekhoubad et al., 2012). This finding calls attention to caveats
associated with using high-passage female hiPSCs to model
X-linked disease. For cell replacement therapy, any phenotypic
abnormality is undesirable and limits the use of iPSC-derived
somatic cells. It has been reported that hemangioblasts derived
from hiPSCs exhibit limited proliferative capacity compared to
hESC-derived hemangioblasts (Feng et al., 2010), which dimin-
ishes the clinical potential of these hiPSCs. Such a functional
difference may result from the genetic or epigenetic variations
in hiPSCs.
When iPSCs are derived for cell replacement therapy, it is
important to evaluate the tumorigenic potential of these iPSCs
and their derivatives before clinical application. First, increased
tumorigenic potential has been found in culture-adapted iPSCs,
which should be avoided. Second, genetic variations inherited
from source cells or introduced during reprogramming may
also facilitate oncogenesis if variations affect oncogene or tumor
suppressor gene functions. Extensive genomic and epigenomic
profiling should be performed to exclude the iPSC lines with
potential oncogenic risk. Finally, an earlier study demonstrated
that, for the oncogenic potential of reprogramming factors,
especially that of c-Myc, leaky silencing or reactivation of trans-
genes would highly increase the oncogenic potential of iPSCs
(Okita et al., 2007); however, this risk can be eliminated by using
nonintegrating transduction methods, which now are robust
enough for routine iPSC derivation.
Although iPSCs are presumed to be autologous to the donor
animals, the possibility that iPSCs or iPSC-derived somatic cells
might be immunogenic was recently investigated and discussed
(Araki et al., 2013; Guha et al., 2013; Okita et al., 2011; Zhao
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genicity from iPSC-derived terminally differentiated cells, which
should be the most commonly used cells for replacement ther-
apy (Araki et al., 2013; Guha et al., 2013). However, it remains
possible that immune response can be elicited by aberrant
gene expression caused by genetic or epigenetic variations in
iPSCs. In addition, although less studied and not the focus of
this Perspective, differentiation from iPSCs to somatic cells
may also introduce aberrations in the genome or epigenome.
In fact, it has been shown that the in vitro differentiation process
is associated with accumulation of genetic alterations (Laurent
et al., 2011). The potential differentiation-induced abnormalities
can cause functional consequences similar to those caused by
genetic or epigenetic variations in iPSCs. Further studies are
required to clarify the genomic and epigenomic stability during
the in vitro differentiation process.
Coping with Genetic and Epigenetic Variations in iPSCs
At least two strategies can be used to cope with the genetic and
epigenetic variations in iPSCs. One is to minimize genetic and
epigenetic variations between iPSC lines; the other is to compre-
hensively characterize the iPSC lines and avoid using iPSC lines
with potentially problematic variations.
Reduction of Variations
A logical way to minimize genetic and epigenetic variations
between iPSC lines is to aim at reducing the causes of variations
in source cells, reprogramming protocols, and culture condi-
tions. With regards to source cells, ideally cells with the least
accumulated genetic mutations should be used. Therefore,
when selecting source cells, cells from embryonic or juvenile
tissues are preferred over cells from adult or aged ones. In addi-
tion, selection of somatic cell types should also be considered. A
recent study indicated that cell types with higher reprogramming
efficiency correlate with fewer DNA methylation abnormalities
during reprogramming (Ruiz et al., 2012), suggesting that
optimizing source cell type may reduce epigenetic variability of
hiPSC lines. Finally, investigations of somatic cell genetic mosa-
icism, which are relatively sparse, may help to identify ideal
source cell types for iPSC generation.
Another factor affecting iPSC variability and safety is the
reprogramming protocol utilized. Nonintegrating methods for
introduction of reprogramming factors can eliminate the risk of
transgene reactivation and genome editing-associated muta-
genesis; hence, they should be routinely applied to derivation
of iPSCs that are designated for clinical application. A deeper
understanding of reprogramming mechanisms would help us
develop an iPSC generation protocol that maximally protects
genomic integrity and maintains epigenetic fidelity during
reprogramming. Lessons can be learned from somatic cell
nuclear transfer (SCNT), which has also been successfully
used in human cells recently (Tachibana et al., 2013), as SCNT
appears to be more efficient and presumably introduces less
stress to somatic cell nucleus. Recently, oocyte factor Zsan4
has been shown to facilitate iPSC generation and reduce the
amplitude of DDR in at least certain settings of reprogramming,
indicating that Zsan4 may reduce the risk of genome instability
during reprogramming (Hirata et al., 2012; Jiang et al., 2013).
For epigenetic variations, manipulating the stoichiometry of
reprogramming factors and inclusion of certain chemicals duringreprogramming has been shown to reduce epigenetic aberrancy
in iPSCs (Carey et al., 2011; Stadtfeld et al., 2012). Therefore,
mechanistic studies in iPSC generation can provide hints for
increasing the genetic and epigenetic fidelity of iPSCs.
Propagation of iPSCs after reprogramming is necessary for
obtaining sufficient cell numbers for downstream studies and
applications. The genetic and epigenetic variability of iPSCs
can be reduced by cell passaging because this reduces certain
mosaic CNVs and eliminates somatic cell memory. However,
certain genetic and epigenetic alterations favoring iPSC propa-
gation can dominate the culture after extensive passaging.
Therefore, it is important to balance these two factors when
considering the optimal passage number of iPSCs for down-
stream applications. As far as we know, few culturing conditions
or manipulations have been correlated to the genetic or epige-
netic variability detected in iPSCs. One exception is that the
XaXa epigenetic status of X chromosomes in hiPSCs is linked
to coculture of LIF-secreting feeder cells (Tomoda et al., 2012).
Nevertheless, stress reduction in culture is a common theme
for maintaining homeostasis of in vitro cultured PSCs, and usage
of chemically defined medium should help eliminate culture var-
iations that may influence the status of iPSCs. Finally, lab-spe-
cific variability between iPSC lines (Newman and Cooper,
2010) can be dismissed if systematic evaluation with multiple
iPSC lines is carried out simultaneously within the same settings.
Although it is feasible to reduce genetic and epigenetic varia-
tions by limiting their sources, having a certain level of genetic
and epigenetic variability is a unanimous feature of all biological
systems, including PSCs. Therefore, rather than trying to derive
iPSC lines completely free of alterations, it is more practical to
obtain iPSC lines that can be used for application purposes
but may contain trivial variations that are functionally negligible.
Alternatively, other approaches that do not involve reprogram-
ming to the pluripotent stage—for example, direct lineage con-
version—should be explored and compared to the iPSC-based
therapeutic strategy.
Detection and Monitoring of Variations
Detecting adverse genetic and epigenetic variations in iPSCs
and monitoring iPSCs throughout passages enables us to avoid
using potentially problematic cell lines for downstream applica-
tions. It also helps to maintain homeostasis of individual iPSC
lines during passaging. Depending on the requirements of
specific downstream applications, a wide range of analyses
can be performed. Basic characterizations, such as karyotyping
and expression analysis of pluripotent markers, should be per-
formed routinely for iPSCs during their passaging. Functional
analyses, including embryoid body formation or teratoma anal-
ysis, can be used to assess the differentiation and oncogenic
potential of iPSCs and should be performed if these properties
are critical for downstream applications. The iPSC lines destined
for therapeutic application should be characterized more exten-
sively. Genome-wide sequencing, expression analysis, and DNA
and histone modification analysis have been used for compre-
hensive genetic and epigenetic profiling of iPSC lines. More
cost-effectively, locus-specific analysis may be performed at
developmentally important genes, cancer-related genes, and
altered hotspots (e.g., aberrant methylation hotspots or X chro-
mosomes). In the long run, to satisfy the need for therapeutic
replacement of different tissue and cell types, it would be idealCell Stem Cell 13, August 1, 2013 ª2013 Elsevier Inc. 155
Figure 2. Genetic and Epigenetic Variations and Their Causes, Functional Consequences, and Impacts on Applications
iPSCs derived from transcription factor (TF)-mediated reprogrammingmay bear different types of genetic (blue boxes) or epigenetic (purple boxes) variations that
can be introduced from varied sources (gray boxes) during the derivation and manipulations of iPSCs. These variations may lead to different functional con-
sequences (red boxes) that need to be considered when iPSCs or their derivatives are used for applications (green boxes). Solid lines, reported or definite
connections; dotted lines, potential connections.
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Perspectiveto set up a bank of hiPSC and hESC lines from various MHC
types, and each line should contain detailed genetic and epige-
netic profiles and differentiation potential ‘‘score cards’’ (Bock
et al., 2011; Taylor et al., 2012).
Conclusion
Genetic and epigenetic variations in iPSCs come from different
sources. Some of the variations may be inherited from donor
somatic cells, induced or selected by the reprogramming pro-
cess, or accumulated during culturing; others may simply reflect
the innate genetic and epigenetic stability of the pluripotent state
of iPSCs (Figure 2). Although each variation is not relevant to the
functionality of iPSCs, certain variations may change the proper-
ties of iPSCs and their derivatives. For example, the variations
may alter the differentiation potential of iPSCs, cause phenotypic
changes in iPSC-derived somatic cells, or increase the tumorige-
nicity or immunogenicity of iPSCs and their derivatives. These
adverse changes directly affect the utility of iPSCs (Figure 2).
Optimizing the reprogramming strategy and culture conditions
helps reduce the occurrence of variations. Comprehensive char-
acterization and rigorous monitoring of genome and epigenome
integrity can ensure the quality of iPSCs designated for down-
stream applications. Additional studies on the mechanism of
iPSC generation will further reveal the ontology of genetic and
epigenetic variations and will provide better solutions for over-
coming the limitations caused by these variations.156 Cell Stem Cell 13, August 1, 2013 ª2013 Elsevier Inc.ACKNOWLEDGMENTS
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